For the quarter ended June 2025, Stryker (SYK) reported revenue of $6.02 billion, up 11.1% over the same period last year. EPS came in at $3.13, compared to $2.81 in the year-ago quarter.
The reported revenue represents a surprise of +1.09% over the Zacks Consensus Estimate of $5.96 billion. With the consensus EPS estimate being $3.06, the EPS surprise was +2.29%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales by Geography- Orthopaedics- Hips- United States: $283 million versus $279.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.
- Net Sales by Geography- Orthopaedics- Knees- United States: $460 million compared to the $462.74 million average estimate based on three analysts. The reported number represents a change of +6.2% year over year.
- Net Sales by Geography- Orthopaedics- Hips- International: $183 million versus the three-analyst average estimate of $181.41 million. The reported number represents a year-over-year change of +9.6%.
- Net Sales by Geography- Orthopaedics- International: $675 million compared to the $739.65 million average estimate based on three analysts. The reported number represents a change of +0.2% year over year.
- Net Sales by Geography- Orthopaedics: $2.25 billion versus the six-analyst average estimate of $2.29 billion. The reported number represents a year-over-year change of -2.3%.
- Net Sales by Business- MedSurg and Neurotechnology: $3.77 billion compared to the $3.68 billion average estimate based on six analysts. The reported number represents a change of +21% year over year.
- Net Sales by Geography- Orthopaedics- Knees: $640 million versus $641.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
- Net Sales by Business- MedSurg and Neurotechnology- Medical: $990 million versus the four-analyst average estimate of $985.69 million. The reported number represents a year-over-year change of +9%.
- Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $899 million compared to the $835.42 million average estimate based on four analysts. The reported number represents a change of +17.1% year over year.
- Net Sales by Geography- Orthopaedics- Hips: $466 million versus $457.77 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.
- Net Sales by Geography- Orthopaedics- Other: $183 million versus the four-analyst average estimate of $194.65 million. The reported number represents a year-over-year change of +34.6%.
- Net Sales by Geography- Orthopaedics- Trauma and Extremities: $957 million compared to the $916.05 million average estimate based on four analysts. The reported number represents a change of +15% year over year.
View all Key Company Metrics for Stryker here>>>
Shares of Stryker have returned -0.7% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
